Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2Not yet recruiting 2Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 7Sarcoma 2Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1CNS 1Breast 1

Conditions

Sarcoma 2Histiocytoma, Malignant Fibrous 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Chondrosarcoma 1

Interventions

Doxorubicin 25Radiotherapy 16apatinib 15Cyclophosphamide 15Ifosfamide 13anlotinib 12camrelizumab 10Temozolomide 9Imatinib Mesylate 9Vincristine 8Surgical Procedures, Operative 7Neoadjuvant Therapy 7Methotrexate 7Drug Therapy 7Dactinomycin 5Blood Specimen Collection 5fludarabine phosphate 4Paclitaxel 4Immune Checkpoint Inhibitors 4Etoposide 4Docetaxel 4Carboplatin 4toripalimab 3pembrolizumab 3Trabectedin 3Topotecan 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × envafolimab × Sarcoma × Clear all
NCT04480502 2024-05-17

ENVASARC

Tracon Pharmaceuticals Inc.

Phase 2 Unknown
207 enrolled
Sarcoma

Sarcoma, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡